Search details
1.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Oncologist
; 21(2): 150-5, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26786263
2.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Oncologist
; 21(6): 778, 2016 06.
Article
in English
| MEDLINE | ID: mdl-27317735
3.
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase â ¡ trial.
Eur J Cancer
; 148: 382-394, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33794440
Results
1 -
3
de 3
1
Next >
>>